Teva drug meets endpoints in celiac disease trial...

Science and health | Sep 2, 2026, 2:52 PM

Teva Pharmaceutical Industries reported that its antibody TEV-408 met the primary endpoints in a clinical trial targeting celiac disease.

The same anti-IL-15 antibody also produced encouraging results when tested as a treatment for vitiligo.

PRO: see who's reacting and what you're missing. See the whole picture →